MedicalResearch.com Interview with:
Lotus Mallbris, M.D., Ph.D.,
Vice president, Immunology Development
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: By exploring creative clinical approaches and patient-centric pathways to more thoroughly address the key aspects of treating these complex conditions, Lilly is bringing innovation forward in hopes of reducing the burden of dermatologic disease for people around the world.
The results of the IXORA-S study suggest that Taltz may provide significantly greater clearance of nail psoriasis than ustekinumab. This is significant because nail lesions are a common feature of psoriasis. It’s often associated with discomfort, which can lead to functional impairment and distress, further supporting the importance of complete clearance. Continue reading